期刊
ARTHRITIS RESEARCH & THERAPY
卷 24, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13075-022-02835-5
关键词
Pulmonary hypertension; Systemic sclerosis; Echocardiography; Minimal detectable difference
类别
资金
- Johns Hopkins Clinician Scientist Award
- Scleroderma Foundation
- Italian Society of Cardiology-Merck Sharp Dohme Grant
- NIH/NIAMS [R01-AR073208]
- NIH/NHLBI [K23-HL153781, K23-HL146889, R01-HL114910]
- Department of Defense [PR191839]
- Scleroderma Research Foundation
The study demonstrates minimal measurement error in clinically important 2DE-based measures in SSc patients, with implications for PAH screening, therapeutic response assessment, and sample size calculations for future clinical trials.
Background Echocardiography (2DE) is integral for screening and longitudinal evaluation of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). In the present study, we sought to establish the reliability, repeatability, and reproducibility of 2DE parameters in SSc patients with and without PAH and to define the minimal detectable difference (MDD), the smallest change detected beyond measurement error. Methods SSc patients without known PAH and with invasively confirmed PAH on stable therapies underwent 2DE with strain at two time points. Analysis of variance (ANOVA) and coefficients of variation (CV) were calculated to assess for repeatability, reliability, and reproducibility. Intra- and inter-observer agreement were assessed using intraclass correlation. Bland-Altman analysis explored the level of agreement between evaluations. MDD was calculated using the standard error of measurement for each parameter by cohort. Results ANOVA demonstrated few significant differences between evaluations across groups. Global right ventricular longitudinal systolic strain (GRVLSS, 9.7%) and fractional area change (FAC, 21.3%) had the largest CV, while tricuspid annular plane excursion (TAPSE), S' wave, and right ventricular outflow track velocity time integral (RVOT VTI) were 0.87%, 3.2%, and 6.0%, respectively. Intra- and inter-observer agreement was excellent. MDD for TAPSE, FAC, S' wave, RVOT VTI, GRVLSS, and RVSP were 0.11 cm, 0.03%, 1.27 cm/s, 0.81 cm, 1.14%, and 6.5 mmHg, respectively. Conclusions We demonstrate minimal measurement error in clinically important 2DE-based measures in SSc patients with and without PAH. Defining the MDD in this population has important implications for PAH screening, assessment of therapeutic response, and sample size calculations for future clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据